Theracryf Statistics

Total Valuation

Theracryf has a market cap or net worth of GBP 5.00 million. The enterprise value is 3.80 million.

Market Cap	5.00M
Enterprise Value	3.80M

Important Dates

The next estimated earnings date is Wednesday, May 28, 2025.

Earnings Date	May 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Theracryf has 2.13 billion shares outstanding. The number of shares has increased by 27.13% in one year.

Current Share Class	n/a
Shares Outstanding	2.13B
Shares Change (YoY)	+27.13%
Shares Change (QoQ)	+54.25%
Owned by Insiders (%)	30.05%
Owned by Institutions (%)	28.43%
Float	1.27B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.88
P/TBV Ratio	3.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.30
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.36

Current Ratio	4.36
Quick Ratio	4.36
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -88.54% and return on invested capital (ROIC) is -63.55%.

Return on Equity (ROE)	-88.54%
Return on Assets (ROA)	-56.06%
Return on Invested Capital (ROIC)	-63.55%
Return on Capital Employed (ROCE)	-125.82%
Revenue Per Employee	n/a
Profits Per Employee	-324,778
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.67% in the last 52 weeks. The beta is 1.29, so Theracryf's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	-68.67%
50-Day Moving Average	0.23
200-Day Moving Average	0.58
Relative Strength Index (RSI)	42.29
Average Volume (20 Days)	1,521,620

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-3.34M
Operating Income	-3.36M
Pretax Income	-3.35M
Net Income	-2.92M
EBITDA	-3.32M
EBIT	-3.36M
Earnings Per Share (EPS)	-0.01

Full Income Statement

Balance Sheet

The company has 1.20 million in cash and n/a in debt, giving a net cash position of 1.20 million or 0.00 per share.

Cash & Cash Equivalents	1.20M
Total Debt	n/a
Net Cash	1.20M
Net Cash Per Share	0.00
Equity (Book Value)	2.67M
Book Value Per Share	0.01
Working Capital	1.57M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-3.11M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Theracryf does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.13%
Shareholder Yield	-27.13%
Earnings Yield	-58.41%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Theracryf has an Altman Z-Score of -11.39. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.39
Piotroski F-Score	n/a